Top London Biotech Companies (113)
Don't see your company?
Create a company profile
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
We are a biotech company developing microbiome-based female health products. Our patented bioactive intimate serum helps to fight bad bacteria for improved urinary tract and intimate health.
At AviadoBio our mission is to potentially transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. It starts here.
At Touchlight we are revolutionising DNA. Our Company and technology is built on the conviction that DNA is fundamental to the future of medicine. By moving away from today's restrictive biological approaches, we have made DNA simple. Our unique dbDNA™ (or "doggybone" DNA) vector is optimised for use in advanced genetic medicines, being safer and more efficacious than conventional plasmid DNA. The platform, based on enzymatic technology, enable DNA production at unprecedented scale, speed and purity. We are leveraging our platform to develop the next generation of DNA vaccines for oncology and infectious diseases, in house and in collaboration with industry partners and academics, as well as enabling manufacture of advanced therapies (viral vectors, mRNA vaccines, and cell therapies) through our CDMO, Touchlight DNA Services.
Wellcome supports science to solve the urgent health challenges facing everyone. We’re a global charitable foundation. And we want everyone to benefit from science’s potential to improve health and save lives. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, climate and health and infectious diseases. Ask us questions, comment on posts and share your thoughts with us. We want to spark conversations, inspire debate and create new collaborations. Find out more about Wellcome: https://wellcome.org/who-we-are
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, medtech industry professionals and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The Company was spun out from the University of Oxford in 2021 and is backed by Oxford Science Enterprises and 8VC
Our team of scientists and product experts are on a mission: developing Sensory Intelligence to seamlessly anchor machines into physical reality. Exciting things are in the pipeline... Stay tuned! #SensoryIntelligence #FutureOfMachines
At AviadoBio our mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Clustermarket is the world-leading lab management system helping laboratories optimize their operations and accelerate results. Clustermarket equips research teams with an easy-to-use software solution enabling them to coordinate equipment usage, plan maintenance activities, and generate reports and forecasts for resource planning. The intuitive system is designed for fast implementation and high adoption within the organization, whilst also offering integrations with various other software solutions
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.
Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain
Hyris is an innovation-based, fast-growing biotech Company, which aims to democratize genetic analysis by offering its partners and clients a disruptive System which enables genetic testing of biological samples in any setting, at any time. When diagnostic and genetic analysis must be performed under the harshest conditions, Hyris checks all the boxes.
Talent experts providing scalable, bespoke recruitment solutions for growing Life Science companies. We have experienced teams of recruiters who can advise and hire across all areas within: • Pharmaceutical • Biotechnology • CRO Services • Health Technology • Medical Devices Our services include contingent, retained, and embedded services, our own version of scaled RPO – suited to rapidly growing organisations. We also offer an investment platform, allowing fledgling SME’s access to our large network of qualified investors, VC’s and PE’s. We recruit extensively across APAC, EMEA & the USA and alongside our London HQ we have opened our West Coast office in June 2022, following Europe expansion to Germany and Switzerland later on this year. Our leadership and recruitment teams have seen the challenges growing Life Science organisations face, hence why we tailor each search to you and give valuable advice based on past experiences working with organisations that have faced your exact challenges. If you are interested to know what we can do for you - reach out and ask for our extensive list of case studies and testimonials from some of the most well-known and recognised companies in the world. We want to continue to make an impact on the incredible advancements within the Life Sciences industry and do this through connecting brilliant talent with brilliant companies
Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information on our company, please visit www.Exagen.com. For more information on AVISE testing services, please visit www.AviseTest.com. Read our Social Media Terms of Use here: http://bit.ly/smtou
MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.
MicrofluidX presents the Cyto Engine, a unified bioreactor and data platform for cell and gene therapy research, development, and manufacturing
Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and clinical testing, to microbiome analysis, and support on formulation development and certification. (www.sequential.bio) Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, Corundum Systems Biology, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo
GlamorousAI is bringing drugs to every target though its AI-first SaaS platform for drug discovery, RosalindAI. RosalindAI advancing AI to address small, noisy and sparse data challenges with a technology validated experimentally in the lab.
Work Your Passion. Live Your Purpose.
